December 16, 2016
Novartis’s epilepsy drug gets CHMP’s positive opinion
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
December 16, 2016
ABIVAX welcomes Didier Blondel as CFO
ABIVAX has appointed Didier Blondel as Chief Financial Officer, effective January 2nd, 2017.
December 16, 2016
FDA OK’s Cerenis’s CER-209 clinical trial for liver disease treatment
U.S. Food and Drug Administration (FDA) has given green light to Cerenis Therapeutics to proceed with CER-209 clinical trial.
December 16, 2016
Novartis buys Ziarco Group
Novartis has entered into a definitive agreement to buy a privately held company Ziarco Group Limited, focused on producing dermatology…
December 16, 2016
RAC Approves Cellectis’s UCART123 Phase 1 study protocols in AML and BPDCN
Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has announced the National Institute…
December 16, 2016
MDxHealth Receives ISO 13485:2016 Certification for Dutch Laboratory
MDxHealth’s laboratory in Nijmegen, The Netherlands has received ISO 13485:2016 certification for the design, development, manufacture and distribution of in…
December 16, 2016
Allergan’s subsidiaries Forest to pay $38M for bad marketing practices
Allergan’s indirect subsidiaries Forest Laboratories, LLS and Forest Pharmaceuticals, Inc. are about to pay $38 million for bad sales and…
December 16, 2016
Valneva closes private placement in connection with EUR15.2m investment by MVM
French vaccines developer Valneva has closed the share issuance in connection with MVM Life Science Partners LLP`s investment in the…
December 15, 2016
COMP gives positive opinion on Hansa Medical’s orphan drug
Hansa Medical, a biopharmaceutical company focusing on novel immunomodulatory enzymes, has announced that the Committee for Orphan Medicinal Products (COMP)…
December 15, 2016
Results of filgotinib Gilead’s study in Chron’s
Galapagos has tested its filgotinib – JAK1 inhibitor – in a phase 2 study, for the patients with Chron’s disease, and…